Related Experiment Video
Updated: Dec 22, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Oxaliplatin-induced Pulmonary Toxicity: A Rare but Serious Complication
Krishna H Suthar1, Salwan Al Mutar2, Rohit Venkatesan3
1Internal Medicine, University of Texas Medical Branch, Galveston, USA.
Abstract:
The FOLFOX regimen (oxaliplatin, leucovorin, and 5-fluorouracil) is FDA approved for use in patients with colorectal cancer and other gastrointestinal malignancies. The initial phase III randomized controlled trials that led to FDA approval of oxaliplatin with leucovorin and 5-fluorouracil showed a less than 1% incidence of pulmonary fibrosis and grade IV pulmonary toxicities. Here we describe two cases of pulmonary toxicity in patients with metastatic colorectal cancer treated with FOLFOX and briefly review the literature regarding oxaliplatin-induced pulmonary toxicity.
Related Concept Videos
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax-II
Clinical Manifestations:
Other Pulmonary Disorders
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

